MATCHPOINT THERAPEUTICS Trademark

Trademark Overview


On Tuesday, January 11, 2022, a trademark application was filed for MATCHPOINT THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the MATCHPOINT THERAPEUTICS trademark a serial number of 97977492. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, July 11, 2024. This trademark is owned by EoCys Inc.. The MATCHPOINT THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development in the field of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease; drug development and discovery services in the field of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease; scientific research in the field of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease; providing scientific research information in the field of pharmaceuticals for the treatment of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease
matchpoint therapeutics

General Information


Serial Number97977492
Word MarkMATCHPOINT THERAPEUTICS
Filing DateTuesday, January 11, 2022
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, July 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 11, 2023

Trademark Statements


Pseudo MarkMATCH POINT THERAPEUTICS
NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesPharmaceutical research and development in the field of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease; drug development and discovery services in the field of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease; scientific research in the field of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease; providing scientific research information in the field of pharmaceuticals for the treatment of oncologic, autoimmune, inflammatory, metabolic, rheumatic, dermatological, endocrine, ophthalmologic, neurologic, cardiovascular, gastrointestinal, and viral disease

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 18, 2022
Primary Code042
First Use Anywhere DateFriday, September 30, 2022
First Use In Commerce DateFriday, September 30, 2022

Trademark Owner History


Party NameEoCys Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Party NameEoCys Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Friday, January 14, 2022NEW APPLICATION ENTERED
Tuesday, January 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, October 19, 2022ASSIGNED TO EXAMINER
Friday, November 4, 2022NON-FINAL ACTION WRITTEN
Friday, November 4, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 4, 2022NON-FINAL ACTION E-MAILED
Thursday, May 4, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 4, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 5, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 21, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, July 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 5, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, January 5, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 5, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 5, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 5, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, January 24, 2024DIVISIONAL REQUEST RECEIVED
Wednesday, January 24, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, January 24, 2024TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, February 7, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 16, 2024DIVISIONAL PROCESSING COMPLETE
Friday, February 16, 2024STATEMENT OF USE PROCESSING COMPLETE
Wednesday, January 24, 2024USE AMENDMENT FILED
Wednesday, March 27, 2024SU - NON-FINAL ACTION - WRITTEN
Wednesday, March 27, 2024NON-FINAL ACTION E-MAILED
Wednesday, March 27, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 11, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, July 11, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND